A novel class of antibiotics to combat Antimicrobial Resistance

Project Information

OMN6

Grant agreement ID: 966627

DOI

10.3030/966627

Project closed

EC signature date 1 June 2021

Start date 1 July 2021

End date 31 October 2023

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 3 413 821,00

EU contribution

€ 2 389 674,70

Coordinated by

OMNIX MEDICAL LTD
Israel

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

OMN6 a novel bioengineered peptide for the treatment of multidrug resistant Gram negative bacteria

Author(s): Shira Mandel, Janna Michaeli, Noa Nur, Isabelle Erbetti, Jonathan Zazoun, Livia Ferrari, Antonio Felici, Moshe Cohen-Kutner , Niv Bachnoff
Published in: Scientific Reports, Issue 2021, March, 23, 2021, Page(s) 6603, ISSN 2045-2322
Publisher: Nature Publishing Group
DOI: 10.1038/s41598-021-86155-9

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

Author(s): Janna Michaeli, Shira Mandel, Shelly Maximov, Jonathan Zazoun, Paola Savoia, Nimmi Kothari, Thomas Valmont, Livia Ferrari, Leonard R. Duncan, Stephen Hawser, Moshe Cohen-Kutner, Niv Bachnoff
Published in: Antibiotics, Issue 2022, 11, August, 2022, Page(s) 1201, ISSN 2079-6382
Publisher: MDPI
DOI: 10.3390/antibiotics11091201